



ORAL SURGERY

ORAL MEDICINE

ORAL PATHOLOGY

CLINICOPATHOLOGIC CONFERENCE*Editor: John R. Kalmar***Refractory localized “periodontitis”**

Rafik A. Abdelsayed, DDS, MS,^a and Omar Sanguenza, MD,^b Augusta, Ga
 MEDICAL COLLEGE OF GEORGIA

(Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:394-8)

CASE REPORT

A 61-year-old male patient presented to his family dentist with a painful and loose tooth, #24, associated with localized gingival enlargement, for several weeks' duration. Besides heavy tobacco and alcohol use, his medical history was otherwise unremarkable. Initial radiographic examination showed a radiolucency with irregular, poorly defined borders in the interproximal area between teeth #24 and #25 (Fig 1, A). The dentist suspected localized inflammatory periodontal disease. Local scaling and root planning were performed, and the patient was placed on strict oral hygiene measures. Two weeks later, increased tooth mobility was noted with lateral extension of the area of gingival enlargement to include teeth #23 and #25. Tooth #24 was extracted, and the patient was prescribed amoxicillin (500 mg, 1 tablet every 6 hours for 7 days). Three weeks later, the extraction site of tooth #24 remained unhealed (Fig 1, B), and teeth #23 and #25 were mobile. Both teeth were extracted with surgical removal of the enlarged gingival tissue, and the patient was placed on a second course of amoxicillin. At the postoperative visit, an ulcerative process involving the anterior mandibular alveolar ridge was seen (Fig 2). The ulcer had rolled borders with extension into both the floor of the mouth and the mucolabial fold. Radiographic examination showed a 2.5-cm osteolytic defect in the anterior mandibular ridge with irregular and ill-defined borders. The patient was then referred to the School of Dentistry at the Medical College of Georgia for evaluation.

Differential diagnosis

Initially, the radiographic and clinical features in this case were thought to be consistent with localized, inflammatory periodontal disease. Yet, despite local debridement and antibi-

otic therapy, evidence of a destructive lesional process was noted. In the differential diagnosis, specific infection, eosinophilic granuloma, squamous cell carcinoma, lymphoma, and metastatic disease were considered. A specific infection, such as mycobacteria or deep fungal forms, was a possible suspect. These types of infection may cause significant bone destruction, mobility of teeth, and necrotic ulceration. Although typically a disease of young individuals, with more than 50% of cases arising during the first two decades, eosinophilic granuloma (monostotic Langerhans cell disease) may be seen over a wide age range. In the jaws, eosinophilic granuloma often appears as an irregular, noncorticated radiolucency of the tooth-bearing alveolar ridge. With proliferation of the gingival soft tissue and tooth mobility, the clinical presentation of eosinophilic granuloma can be reminiscent of local periodontal disease. Squamous cell carcinoma, originating either from the gingival or sulcular surface epithelium or centrally from odontogenic epithelium, was also considered. Squamous cell carcinoma in these locations may cause bone destruction, root resorption, and mobility of teeth. Radiographically, lesions often appear as an ill-defined, moth-eaten radiolucency with irregular borders. Extranodal lymphoma was included in the differential. Lymphoma may be present in the jaws with irregular bony destruction and may be associated with soft tissue mass and tooth mobility, mimicking periodontal disease. Finally, although the patient reported no history of cancer, the possibility of metastatic disease from unknown primary was also considered.

Diagnosis

An incisional biopsy was performed at the periphery of the ulcerative process. Routine histopathologic examination showed a diffuse, cellular infiltrate of large and smaller-sized, round to oval cells (Fig 3). The large neoplastic cells had prominent basophilic nuclei and abundant cytoplasm that varied from eosinophilic to optically clear (Fig 4). A plasma-cytoid morphology was noted focally within the population of smaller cells. Nuclear hyperchromatism and atypical mitotic figures were readily identified. The neoplastic cells were strongly positive for CD45 (leukocyte common antigen) and CD20, a B-cell marker (Fig 5), but negative for T-cell

^aAssociate Professor, Oral and Maxillofacial Pathology Department, School of Dentistry.

^bProfessor, Department of Pathology and Medicine (Dermatology Section).

Received for publication Jan, 1999; returned for revision Sep 20, 2000; accepted for publication Oct 30, 2001.

© 2002 Mosby, Inc. All rights reserved.

1079-2104/2002/\$35.00 + 0 7/14/121434

doi:10.1067/moe.2002.121434




Fig 1. **A**, Preoperative radiograph showing interproximal radiolucency. **B**, Periapical film showing a crater-shaped radiolucency with irregular borders 3 weeks after extraction of tooth #24.



Fig 2. Large ulcer involving the anterior mandibular alveolus, floor of mouth, and mucolabial fold.

markers. Probes for α and λ light chains showed kappa light chain restriction.

The final diagnosis was immunoblastic lymphoma, B-cell type.

Management

On hospital admission, extensive patient workup including complete physical examination, complete blood count with differential, blood chemistry, and bone marrow aspiration showed no additional abnormal findings. The patient received 4 cycles of multiple-drug chemotherapy consisting of Cytosar 750 mg/m², adriamycin 50 mg/m², vincristine 1.4 mg/m² intravenously, and prednisone 100 mg/m² orally. After the first 2 cycles, the patient developed pharyngitis, laryngitis, and epigastric distress but tolerated the remaining treatments

reasonably well. The oral lesion totally resolved before completion of chemotherapy. Posttreatment evaluation of the patient's head and neck with computed tomography and gallium scans was negative for tumor. The patient was subsequently lost to follow-up.

DISCUSSION

Immunoblastic lymphoma (IBL) is a high-grade neoplasm that comprises less than 5% of all lymphomas. According to the recently updated REAL (Revised European-American classification of lymphoid neoplasms) system, IBL remains included within the morphologic subtypes of diffuse, large B-cell lymphomas (DLBCLs).¹⁻⁴ Immunohistochemical




Fig 3. Low-power photomicrograph of the gingival biopsy showing heavy subepithelial infiltration of lymphoid cells (hematoxylin-eosin stain; original magnification $\times 20$).




Fig 4. Medium-power photomicrograph illustrating large and small neoplastic lymphoid cells (hematoxylin-eosin stain; original magnification $\times 200$).

evidence suggests that DLBCLs arise from cleaved and noncleaved cells within the germinal centers of lymph nodes.^{2,5} Several subtypes of DLBCLs, including centroblastic, IBL, and anaplastic large cell (CD30+), have been described.^{2,4} Although IBL was previously thought to develop from reticulum cells or histiocytes, it is now believed to arise from antigenically activated or transformed lymphocytes known as immunoblasts.⁵ This was reflected by the morphologic classification scheme proposed by Schneider et al⁶ in 1985, who designated these cases as immunoblastic sarcoma.

Immunophenotypically, IBL may be separated into T- or B-cell types.^{5,7} The T-cell type is an aggressive neoplasm with a poor prognosis that usually develops in the lymph nodes and is now considered to be among the category of peripheral T-cell lymphomas.^{4,7,8} By contrast, IBL B-cell type develops more frequently in extranodal sites including mediastinum, stomach, neck, lung, diaphragm, testis, and bone, with less frequent origin in the lymph nodes or spleen.^{6,7} IBLs often arise in patients with autoimmune disorders, such as systemic lupus erythematosus, rheumatoid arthritis,




Fig 5. Photomicrograph showing positive reaction of neoplastic cells to the B-cell marker, CD20 (immunoperoxidase $\times 100$).

Hashimoto thyroiditis, and Sjögren's syndrome.^{7,9-11} In one study, a history of immunologic disease was noted in 36% of patients with IBL B-cell type and in 16% of patients with T-cell type.⁷ Benign or low-grade lymphoproliferative conditions, including angioimmunoblastic lymphadenopathy, chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, and well-differentiated lymphocytic lymphoma, may also precede the onset of IBL.^{10,12,13} This feature was reportedly more common with the T-cell type (26%) than with B-cell type cases (13%).⁷ In addition, IBL is one of several lymphoproliferative disorders reported to occur in patients with congenital immune deficiencies, immunosuppressed transplant recipients, as well as patients with acquired immune deficiency syndrome (AIDS).¹⁴⁻¹⁶ These disorders share several common features, including origination in or involvement of extranodal sites, diffuse aggressive histopathologic features, B-cell lineage or differentiation, association with Epstein-Barr virus, and rapid clinical progression.¹⁷

Immunoglobulin (Ig) production, a characteristic feature of terminal B-cell (plasma cell) differentiation, is determined by rearrangement and expression of the genes encoding the heavy and light Ig chains.¹⁸ Strauchen et al¹⁹ reported Ig expression in 254 of 345 (74%) B-cell lymphoma cases. Ig was most frequently expressed by small lymphocytic, small cleaved and noncleaved cell histologic types and occurred less frequently in lymphomas of the large cell (cleaved and noncleaved) and immunoblastic histologic types.

IBL of the oral cavity is extremely uncommon. A search of the literature yielded 12 cases, all of which

occurred in AIDS or human immunodeficiency virus (HIV)-infected patients.²⁰⁻²³ Takahashi et al²⁴ reported an additional 12 cases of IBL among 70 (17%) cases of primary extranodal non-Hodgkin's lymphomas of the oral region. Unfortunately, information regarding HIV-positivity or immunologic status of their patients was not provided. In the current case, IBL developed in the anterior mandibular alveolus in a patient with no known underlying immunologic disorder and without evidence of nodal involvement. Despite clinical similarity to localized, inflammatory periodontal disease, the lack of responsiveness to conventional therapy warranted careful exclusion of a more aggressive, possibly neoplastic condition. Even so, the patient underwent 2 separate extraction procedures without the benefit of biopsy of the associated, abnormal soft tissue. The delay in diagnosis and treatment of our patient is yet another reminder that histopathologic evaluation and diagnosis of clinically abnormal tissues are critical, even in cases of refractory "periodontitis."

REFERENCES

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;84:1361-92.
2. Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel Classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. *Blood* 1997;89:2291-7.
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—

- Airlie House, Virginia, November 1997. *J Clin Oncol* 1999;17:3835-49.
4. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al. Updated Kiel classification for lymphomas. *Lancet* 1988;1:292-3.
 5. Joachim HL. Lymph node pathology, 2nd ed. Philadelphia: J B Lippincott; 1994. p. 417-24.
 6. Schneider DR, Taylor CR, Parker JW, Cramer AC, Meyer PR, Lukes RJ. Immunoblastic sarcoma of T- and B-cell types: morphologic description and comparison. *Hum Pathol* 1985;16:885-900.
 7. Levine AM, Taylor CR, Schneider DR, Koehler SC, Forman SJ, Lichtenstein A, et al. Immunoblastic sarcoma of T-cell versus B-cell origin. I. Clinical features. *Blood* 1981;58:52-61.
 8. Jaffe ES. Post-thymic lymphoid neoplasia. In: Jaffe ES, editor. *Surgical pathology of the lymph nodes and related organs*. Philadelphia: WB Saunders; 1985.
 9. Lichtenstein A, Levine AM, Lukes RJ, Cramer AD, Taylor CR, Lincoln TL, et al. Immunoblastic sarcoma: a clinical description. *Cancer* 1979;43:343-52.
 10. Lukes RJ. The immunologic approach to the pathology of malignant lymphomas. *Am J Clin Pathol* 1979;72(suppl 4):657-69.
 11. Michel RP, Case BW, Moinuddin M. Immunoblastic lymphosarcoma: a light, immunofluorescence and electron microscopic study. *Cancer* 1979;43:224-36.
 12. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy: a hyperimmune entity resembling Hodgkin's disease. *N Engl J Med* 1975;292:1-8.
 13. Fisher RI, Jaffe ES, Braylan RC, Andersen JC, Tan HK. Lymphadenopathy: evolution into a malignant lymphoma with plasmacytoid features. *Am J Med* 1976;61:553-9.
 14. Filipovich AH, Heinritz KJ, Robison LL, Frizzera G. The Immunodeficiency Cancer Registry: a research resource. *Am J Pediatr Hematol Oncol* 1987;9:183-4.
 15. Matas AJ, Hertel BF, Rosai J, Simmoms RL, Najarian JS. Post-transplant malignant lymphoma: distinctive morphologic features related to its pathogenesis. *Am J Med* 1976;61:716-20.
 16. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. *Lancet* 1991;337:805-9.
 17. Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. *Blood* 1989;73:792-9.
 18. Cooper MD. Current concepts: B lymphocytes—normal development and function. *N Engl J Med* 1987;317:1452-6.
 19. Strauchen JA, Mandeli JP. Immunoglobulin expression in B-cell lymphoma: immunohistochemical study of 345 cases. *Am J Clin Pathol* 1991;95:692-5.
 20. Gulley ML, Sargeant KP, Grider DJ, Eagan PA, Davey DD, Damm DD, et al. Lymphomas of the oral soft tissues are not preferentially associated with latent or replicative Epstein-Barr virus. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1995;80:425-31.
 21. Green TL, Eversole LR. Oral lymphomas in HIV-infected patients: association with Epstein-Barr virus DNA. *Oral Surg Oral Med Oral Pathol* 1989;67:437-42.
 22. Jordan RC, Chong L, DiPierdomenico S, Satira F, Main JH. Oral lymphoma in HIV infection. *Oral Dis* 1997;3(suppl 1):S135-7.
 23. Gowdey G, Lipsey LR, Lee R, Jacques C, Northfelt DW. Gingival mass lesions in a patient with HIV infection. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1995;79:7-9.
 24. Takahashi H, Tsuda N, Tezuka F, Okabe H. Primary extranodal non-Hodgkin's lymphoma of the oral region. *J Oral Pathol Med* 1989;18:84-91.
- Reprint requests:*
Rafik A. Abdelsayed, DDS, MS
School of Dentistry
Medical College of Georgia
Augusta, GA 30912-1110
rabdelsa.dentistr@mailgw.mcga.edu